MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference
MBX Biosciences (Nasdaq: MBX), a clinical-stage biopharmaceutical company specializing in precision peptide therapies for endocrine and metabolic disorders, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.
The company's President and CEO, Kent Hawryluk, will deliver a podium presentation on Monday, April 7, 2025, from 8:00 a.m. to 8:40 a.m. ET. The presentation will be accompanied by one-on-one meetings.
Investors can access the live webcast through the investors section of MBX Biosciences' website at investors.mbxbio.com/news-events/events. A replay will be available approximately two hours after the event and will remain accessible for about 90 days on the company's website.
MBX Biosciences (Nasdaq: MBX), un'azienda biofarmaceutica in fase clinica specializzata in terapie peptidiche di precisione per disturbi endocrini e metabolici, ha annunciato la sua partecipazione al 24° Annual Needham Virtual Healthcare Conference.
Il presidente e CEO dell'azienda, Kent Hawryluk, terrà una presentazione sul podio lunedì 7 aprile 2025, dalle 8:00 alle 8:40 ET. La presentazione sarà accompagnata da incontri individuali.
Gli investitori possono accedere alla diretta streaming attraverso la sezione dedicata agli investitori del sito web di MBX Biosciences all'indirizzo investors.mbxbio.com/news-events/events. Una registrazione sarà disponibile circa due ore dopo l'evento e rimarrà accessibile per circa 90 giorni sul sito dell'azienda.
MBX Biosciences (Nasdaq: MBX), una empresa biofarmacéutica en etapa clínica especializada en terapias peptídicas de precisión para trastornos endocrinos y metabólicos, ha anunciado su participación en la 24ª Conferencia Anual Virtual de Atención Médica de Needham.
El presidente y CEO de la empresa, Kent Hawryluk, ofrecerá una presentación en el podio el lunes 7 de abril de 2025, de 8:00 a.m. a 8:40 a.m. ET. La presentación será acompañada de reuniones uno a uno.
Los inversores pueden acceder a la transmisión en vivo a través de la sección de inversores del sitio web de MBX Biosciences en investors.mbxbio.com/news-events/events. Una repetición estará disponible aproximadamente dos horas después del evento y permanecerá accesible durante unos 90 días en el sitio web de la empresa.
MBX 바이오사이언스 (Nasdaq: MBX), 내분비 및 대사 장애를 위한 정밀 펩타이드 치료제에 전문화된 임상 단계의 생명공학 회사가 제24회 니드햄 가상 의료 회의에 참여한다고 발표했습니다.
회사의 회장 겸 CEO인 켄 하우리룩은 2025년 4월 7일 월요일, 오전 8시부터 8시 40분(ET)까지 연단 발표를 진행할 예정입니다. 발표는 일대일 미팅과 함께 진행됩니다.
투자자들은 MBX 바이오사이언스 웹사이트의 투자자 섹션인 investors.mbxbio.com/news-events/events를 통해 생중계를 시청할 수 있습니다. 이벤트가 끝난 후 약 두 시간 후에 다시 보기 기능이 제공되며, 회사 웹사이트에서 약 90일 동안 접근할 수 있습니다.
MBX Biosciences (Nasdaq: MBX), une entreprise biopharmaceutique en phase clinique spécialisée dans les thérapies peptidiques de précision pour les troubles endocriniens et métaboliques, a annoncé sa participation à la 24e Conférence Annuelle Virtuelle de Soins de Santé de Needham.
Le président et PDG de l'entreprise, Kent Hawryluk, fera une présentation sur scène le lundi 7 avril 2025, de 8h00 à 8h40 ET. La présentation sera accompagnée de réunions individuelles.
Les investisseurs peuvent accéder au webinaire en direct via la section investisseurs du site web de MBX Biosciences à l'adresse investors.mbxbio.com/news-events/events. Un enregistrement sera disponible environ deux heures après l'événement et restera accessible pendant environ 90 jours sur le site de l'entreprise.
MBX Biosciences (Nasdaq: MBX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf präzise Peptidtherapien für endokrine und Stoffwechselstörungen spezialisiert hat, hat seine Teilnahme an der 24. jährlichen Needham Virtual Healthcare Conference angekündigt.
Der Präsident und CEO des Unternehmens, Kent Hawryluk, wird am Montag, den 7. April 2025, von 8:00 bis 8:40 Uhr ET eine Podiumspräsentation halten. Die Präsentation wird von Einzelgesprächen begleitet.
Investoren können auf den Live-Stream über den Investorenbereich der Website von MBX Biosciences unter investors.mbxbio.com/news-events/events zugreifen. Eine Wiederholung wird etwa zwei Stunden nach der Veranstaltung verfügbar sein und bleibt etwa 90 Tage auf der Website des Unternehmens zugänglich.
- None.
- None.
CARMEL, Ind., March 26, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at and participate in the 24th Annual Needham Virtual Healthcare Conference.
24th Annual Needham Virtual Healthcare Conference
Date: Monday, April 7, 2025
Format: Podium Presentation and 1x1 meetings
Time: 8:00 a.m. – 8:40 a.m. ET
The live webcast can be accessed in the investors section of the MBX Biosciences website at https://investors.mbxbio.com/news-events/events. Access to the webcast replay will be available approximately two hours after the completion of the event and will be archived on the Company’s website for approximately 90 days.
About MBX Biosciences
MBX Biosciences is a biopharmaceutical company focused on the discovery and development of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism (HP) in Phase 2 development; MBX 1416 for the treatment of post-bariatric hypoglycemia (PBH) in Phase 1 development; and an obesity portfolio that includes MBX 4291, with an IND filing anticipated in Q2 2025, as well as multiple discovery and pre-clinical obesity candidates. The Company is based in Carmel, Indiana. To learn more, please visit the Company website at https://mbxbio.com/ and follow it on LinkedIn.
Media Contact:
Katie Beach Oltsik
Inizio Evoke Comms
katie.beach@inizioevoke.com
(937) 232-4889
Investor Contact:
Jim DeNike
MBX Biosciences
jdenike@mbxbio.com
FAQ
When is MBX Biosciences presenting at the Needham Healthcare Conference 2025?
How can investors watch MBX Biosciences' Needham Conference presentation?
How long will MBX Biosciences' Needham Conference presentation replay be available?
What type of therapies is MBX Biosciences (MBX) developing?
